Get the Stockscreener App
28.38
0.89%
0.25
Genmab Adr stock is traded at $28.38, with a volume of 609.39K.
It is up +0.89% in the last 24 hours and up +10.56% over the past month.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
See More
Previous Close:
$28.13
Open:
$28.18
24h Volume:
609.39K
Market Cap:
$18.01B
Revenue:
$2.58B
Net Income/Loss:
$794.60M
P/E Ratio:
28.32
EPS:
1.0022
Net Cash Flow:
$781.65M
1W Performance:
+2.27%
1M Performance:
+10.56%
6M Performance:
+1.65%
1Y Performance:
-27.49%
1D Range:
$28.14
$28.47
52W Range:
$24.53
$42.72
Genmab Adr Stock (GMAB) Company Profile
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-23-24 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-22-24 | Downgrade | Citigroup | Neutral → Sell |
| Dec-06-23 | Upgrade | UBS | Neutral → Buy |
| Nov-10-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Nov-08-23 | Upgrade | DNB Markets | Sell → Buy |
| Oct-18-23 | Initiated | Exane BNP Paribas | Underperform |
| Sep-06-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-24-23 | Initiated | BTIG Research | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-31-23 | Initiated | UBS | Neutral |
| May-12-23 | Initiated | Morgan Stanley | Underweight |
| Dec-20-22 | Downgrade | Citigroup | Buy → Neutral |
| Nov-14-22 | Initiated | William Blair | Mkt Perform |
| Nov-11-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-24-22 | Initiated | BMO Capital Markets | Market Perform |
| May-02-22 | Initiated | Cowen | Market Perform |
| Mar-16-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-01-21 | Initiated | Berenberg | Sell |
| Sep-16-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-24-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-20-21 | Initiated | Deutsche Bank | Buy |
| Jan-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-20 | Downgrade | Bryan Garnier | Neutral → Sell |
| Sep-08-20 | Initiated | SVB Leerink | Mkt Perform |
| Jun-25-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-23-20 | Initiated | Credit Suisse | Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Dec-12-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Sep-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Sep-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | Morgan Stanley | Overweight |
| Aug-12-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Genmab Adr Stock (GMAB) Latest News
GMAB vs. CSLLY: Which Stock Is the Better Value Option? - Yahoo Finance
Yahoo Finance
GMAB’s Stock Journey: What Investors Need to Know About Genmab ADR’s Performance - The InvestChronicle
The InvestChronicle
Wall Street Analysts Believe Genmab (GMAB) Could Rally 52.33%: Here's is How to Trade - Zacks Investment Research
Zacks Investment Research
Wall Street Analysts Believe Genmab (GMAB) Could Rally 52.33%: Here's is How to Trade - Yahoo Finance Australia
Yahoo Finance Australia
Wall Street Analysts Believe Genmab (GMAB) Could Rally 52.33%: Here's is How to Trade - Nasdaq
Nasdaq
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024 - GlobeNewswire
GlobeNewswire Inc.
Genmab Adr Stock (GMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):